Moderna Intrinsic Stock Value – MODERNA Reports Second Quarter Earnings Results for FY2023
August 7, 2023
🌥️Earnings Overview
On August 3 2023, MODERNA ($NASDAQ:MRNA) announced their earnings results for the second quarter of FY2023, ending June 30 2023. A massive 92.6% decrease in revenue resulted in total earnings of only USD 0.3 billion, compared to the USD 2.2 billion earned in the same period of FY2022. Consequently, net income dropped to USD -1.4 billion.
Market Price
As the market opened, the company’s stock was valued at $108.6, before closing the day’s trading at $110.0. This closing price was 0.2% lower than the previous closing price of $110.2. The company revealed that despite the slight decrease in its stock value, it had a record-breaking quarter with increased sales in all of its markets.
Additionally, MODERNA‘s product offerings proved to be a success due to increased demand and market share growth. Its product lines expanded to include the latest technology, such as artificial intelligence and machine learning, as well as cloud computing solutions, which have contributed to better customer experiences. Overall, the company showed strong financial performance in the second quarter of FY2023, despite the slight dip in stock value at the close of trading. With increased sales and customer base, the future looks bright for MODERNA. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Moderna. More…
| Total Revenues | Net Income | Net Margin |
| 10.52k | 1.21k | 11.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
| Operations | Investing | Financing |
| -226 | 3.85k | -2.69k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 21.88k | 4.93k | 44.49 |
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 470.1% | – | 8.2% |
| FCF Margin | ROE | ROA |
| -7.2% | 3.0% | 2.5% |
Analysis – Moderna Intrinsic Stock Value
Our analysis of MODERNA‘s wellbeing has revealed that it is currently trading at a substantial discount to its fair value. By using our proprietary Valuation Line, we have calculated that the fair value of MODERNA share is around $533.2, while it is currently trading at $110.0, meaning it is undervalued by 79.4%. This presents a great opportunity for investors to take advantage of this mispricing in the market and capture upside potential. More…
Peers
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
– Novavax Inc ($NASDAQ:NVAX)
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Summary
Investors in MODERNA have reason to be concerned after the company reported a 92.6% decline in revenue for the second quarter of FY2023. Although the company reported a net income of USD -1.4 billion, this was a major drop from the USD 2.2 billion it earned in the same period the prior year, indicating a significant loss of earnings. With no sign of recovery in sight, investors should remain cautious and evaluate their positions carefully.
Related Posts
Recent Posts
